Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nasser Altorki

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|February 25, 2023
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trialJay M Lee, Eric Vallières, Beiying Ding, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Propionate metabolism dysregulation promotes drug-tolerant persister cell survival in non-small cell lung cancerBobak Parang, Liron Yoffe, Rabia Khan, et al.
JTCVS Open|May 4, 2026
Sublobar resection is the preferred surgical strategy for clinical stage IA lung cancers presenting as subsolid noduleSebron Harrison, Rowena Yip, Abu Nasar, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerZhan Yao, Silvia Fenoglio, Ding Cheng Gao, et al.
Scientific Reports|March 19, 2026
Propionate metabolism is dysregulated in non-small cell lung cancer patients and EGFR-mutant drug-tolerant persister cellsBobak Parang, Liron Yoffe, Rabia Khan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons databaseEnrico Ruffini, Frank Detterbeck, Dirk Van Raemdonck, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 20, 2025
Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non-small cell lung cancerDan Jones, Abu Nasar, Jonathan Villena-Vargas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic ResponseBryan J Schneider, Manish A Shah, Kelsey Klute, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 19, 2008
Detection of lung cancer using weighted digital analysis of breath biomarkersMichael Phillips, Nasser Altorki, John H M Austin, et al.
Cancer Biomarkers : Section a of Disease Markers|May 25, 2007
Prediction of lung cancer using volatile biomarkers in breathMichael Phillips, Nasser Altorki, John H M Austin, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
The Journal of Thoracic and Cardiovascular Surgery|February 25, 2023
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trialJay M Lee, Eric Vallières, Beiying Ding, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Propionate metabolism dysregulation promotes drug-tolerant persister cell survival in non-small cell lung cancerBobak Parang, Liron Yoffe, Rabia Khan, et al.
JTCVS Open|May 4, 2026
Sublobar resection is the preferred surgical strategy for clinical stage IA lung cancers presenting as subsolid noduleSebron Harrison, Rowena Yip, Abu Nasar, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2010
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerZhan Yao, Silvia Fenoglio, Ding Cheng Gao, et al.
Scientific Reports|March 19, 2026
Propionate metabolism is dysregulated in non-small cell lung cancer patients and EGFR-mutant drug-tolerant persister cellsBobak Parang, Liron Yoffe, Rabia Khan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons databaseEnrico Ruffini, Frank Detterbeck, Dirk Van Raemdonck, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 20, 2025
Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non-small cell lung cancerDan Jones, Abu Nasar, Jonathan Villena-Vargas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic ResponseBryan J Schneider, Manish A Shah, Kelsey Klute, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 19, 2008
Detection of lung cancer using weighted digital analysis of breath biomarkersMichael Phillips, Nasser Altorki, John H M Austin, et al.
Cancer Biomarkers : Section a of Disease Markers|May 25, 2007
Prediction of lung cancer using volatile biomarkers in breathMichael Phillips, Nasser Altorki, John H M Austin, et al.
Pageof 10